Sartans Market is expected to grow at a CAGR of 2.05% during the forecasted period | Evolve Business Intelligence

Key Highlights:
• The global Sartans Market size was valued at USD 25.35 billion in 2022 growing at a CAGR of 2.05% from 2023 to 2033.
• North America dominated the market in 2022
• Asia Pacific is expected to grow at the highest CAGR from 2023 to 2033
As per the study initiated by Evolve Business Intelligence, the global Sartans Market size accounted for USD 25.35 Billion in 2022, growing at a CAGR of 2.05% from 2023 to 2033. The sartans market involves pharmaceuticals belonging to the angiotensin II receptor blockers (ARBs) class, commonly used to treat conditions such as hypertension and heart failure. These medications block the effects of angiotensin II, a hormone that narrows blood vessels, resulting in vasodilation and reduced blood pressure. Widely prescribed due to their efficacy and tolerability, sartans are often recommended as first-line treatments for hypertension. Market growth is driven by the increasing prevalence of cardiovascular diseases, a growing aging population, and the continuous development of sartan-based drugs by pharmaceutical companies.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=openpr.com&reportCode=021738

The sartans market is primarily driven by their widespread use in treating hypertension and heart failure. These angiotensin II receptor blockers (ARBs) offer effective blood pressure management with favorable tolerability. Market growth is fueled by the rising incidence of cardiovascular diseases, an aging population, and ongoing pharmaceutical advancements in developing new sartan-based medications.

Key Players
Some of the major Sartans Market players holding high market shares include Bayer, Astra Zeneca, Eli Lilly and Merck. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Teva Pharmaceutical, Johnson and Johnson, Sanofi, Novartis, Bristol-Myers Squibb, Pfizer.

Report Description: https://report.evolvebi.com/index.php/sample/request?referer=openpr.com&reportCode=021738

Segmental Analysis
Based on Product Type, the Sartans market is segmented into Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan and Olmesartan. the Ibersartan segment dominates the market due to high efficacy in lowering blood pressure and preventing potential kidney damage caused by diabetes.
Based on Application, the Sartans market is segmented into Hypertension, Cardiovascular Diseases, Kidney Diseases and Others. the primary use of sartan medication is to treat high blood pressures though the drug has recently shown other pleotropic applications.
Based on End User, the Sartans market is segmented into Hospitals, Diagnostic Laboratories and Others. the hospitals segment is expected to provide avenue for sale and administration of the drug.

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from fortune's global 2000 companies.

This release was published on openPR.